

**REMARKS**

Claims 22 through 26 are cancelled in view of the Examiner's amendment entered 12/17/2009. These claims were erroneously denoted as being "Withdrawn and currently amended" or "Withdrawn" in the paper filed March 29, 2010.

Claims 49 and 50 are new.

The status identifiers for claims 1-21, 27-46, 47 and 48 in the paper filed March 29, 2010 have been retained in the enclosed amendment.

In addition, a copy of the following reference, "A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo" is brought to the attention of the Examiner to illustrate the state of the art in connection with the biological activity of the claimed compound (CEP-701). This reference is listed on the PTO-1449 accompanying this paper. Consideration of this reference during examination is respectfully requested.

Respectfully submitted,

Date: April 13, 2010

/ Rona A. Nardone /  
Rona A. Nardone  
Registration No. 55,481

Cephalon, Inc.  
41 Moores Road  
PO Box 4011  
Frazer, PA 19355  
Telephone: 610.727.6328  
Telefax: 610.727.7651